Skip to content
by Legal Desire
8 January 2024

Latham Advises Rhythm on Agreement to Acquire Global Rights to Oral MC4R Agonist LB54640 From LG Chem

Advising firms

Deal team

15 lawyers named
LawyerFirmSeniorityPracticeOffice
Steven Chinowsky Lead Latham & Watkins LLP Partner licensing Not stated
Peter Handrinos Lead Latham & Watkins LLP Partner corporate Not stated
Elizabeth Slawsby Lead Latham & Watkins LLP Partner corporate Not stated
Oliver Mobasser Latham & Watkins LLP Associate licensing Not stated
Ami Sodha Latham & Watkins LLP Associate licensing Not stated
Mandy Reeves Latham & Watkins LLP Partner antitrust Not stated
Héctor Armengod Latham & Watkins LLP Partner antitrust Not stated
Patrick English Latham & Watkins LLP Counsel antitrust Not stated
Jennifer Yoon Latham & Watkins LLP Partner public company matters Not stated
Jenna Cooper Latham & Watkins LLP Partner public company matters Not stated
Hamna Ahmad Latham & Watkins LLP Associate public company matters Not stated
Naseem Faqihi Alawadhi Latham & Watkins LLP Associate public company matters Not stated
Kirt Switzer Latham & Watkins LLP Partner tax Not stated
Derek Gumm Latham & Watkins LLP Associate tax Not stated
Darryl Steensma Latham & Watkins LLP Counsel patent diligence Not stated

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
Rhythm Pharmaceuticals, Inc.Buy-side
Counterparties
LG Chem Life Sciences (Sell-side)